Endothelin 1-induced retinal ganglion cell death is largely mediated by JUN activation

Olivia J. Marola, Stephanie B. Syc-Mazurek, Gareth R. Howell and Richard T. Libby

Abstract

Glaucoma is a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs), the output neurons of the retina. Multiple lines of evidence show the endothelin (EDN, also known as ET) system is important in glaucomatous neurodegeneration. To date, the molecular mechanisms within RGCs driving EDN-induced RGC death have not been clarified. The pro-apoptotic transcription factor JUN (the canonical target of JNK signaling) and the endoplasmic reticulum stress effector and transcription factor DNA damage inducible transcript 3 (DDIT3, also known as CHOP) have been shown to act downstream of EDN receptors. Previous studies demonstrated that JUN and DDIT3 were important regulators of RGC death after glaucoma-relevant injures. Here, we characterized EDN insult in vivo and investigated the role of JUN and DDIT3 in EDN-induced RGC death. To accomplish this, EDN1 ligand was intravitreally injected into the eyes of wildtype, Six3-cre\(^{+/−}\) Jun\(^{+/−}\) (Jun[−/−]), Ddit3 null (Ddit3[−/−]), and Ddit3[−/−]Jun[−/−] mice. Intravitreal EDN1 was sufficient to drive RGC death in vivo. EDN1 insult caused JUN activation in RGCs, and deletion of Jun from the neural retina attenuated RGC death after EDN insult. However, deletion of Ddit3 did not confer significant protection to RGCs after EDN1 insult. These results indicate that EDN caused RGC death via a JUN-dependent mechanism. In addition, EDN signaling is known to elicit potent vasoconstriction. JUN signaling was shown to drive neuronal death after ischemic insult. Therefore, the effects of intravitreal EDN1 on retinal vessel diameter and hypoxia were explored. Intravitreal EDN1 caused transient retinal vasoconstriction and regions of RGC and Müller glia hypoxia. Thus, it remains a possibility that EDN elicits a hypoxic insult to RGCs, causing apoptosis via JNK-JUN signaling. The importance of EDN-induced vasoconstriction and hypoxia in causing RGC death after EDN insult and in models of glaucoma requires further investigation.

Introduction

Glaucoma is a neurodegenerative condition affecting the output neurons of the retina—the retinal ganglion cells (RGCs). The mechanisms that cause RGC insult and death in glaucoma remain incompletely understood. Recently, the endothelin (EDN, also known as ET) system has been implicated in glaucomatous neurodegeneration\(^1\)–\(^6\). There are three secreted EDN peptide ligands (EDN1, EDN2, and EDN3) and two EDN membrane-bound receptors (EDNRA and EDNRB). EDN ligands are the most potent vasoactive peptides known, and the canonical role of EDN signaling is to mediate vasoconstriction\(^4\)\(^,\)\(^7\)\(^,\)\(^8\). Changes in blood flow have been documented in human\(^9\)–\(^12\) and animal models\(^5\)\(^,\)\(^6\) of glaucoma, and it is hypothesized that these changes could be important factors in the development and progression of glaucoma. EDN ligands and receptors were found to be upregulated in models of acute\(^13\)\(^,\)\(^14\) and chronic ocular hypertension\(^15\)\(^,\)\(^16\)–\(^17\). Importantly, molecular clustering analysis of transcriptional changes in ocular hypertensive mouse retinas and optic nerve heads revealed that upregulation of Edn ligands and receptors was among the first molecular changes in glaucoma pathology\(^1\)\(^,\)\(^5\)\(^,\)\(^6\). Levels of EDN were also found to be elevated in the aqueous humor.
and plasma of glaucoma patients. Antagonism or knockout of EDN receptors lessened RGC loss in models of acute and chronic ocular hypertension. In addition, EDN delivery was sufficient to drive RGC death in vivo. Despite these findings, the cell death pathways responsible for eliciting RGC death upon EDN insult remain unknown. Understanding the molecular mechanisms controlling EDN-induced RGC death in glaucoma will provide insight into early, critical pathways of glaucomatous neurodegeneration and can identify potential therapeutic targets for neuroprotective glaucoma treatments.

JUN N-terminal kinase (JNK) signaling has been shown to be important in mediating glaucoma-relevant neurodegeneration. JNK signaling is a mitogen activated protein kinase phosphorelay system where MAP3Ks phosphorylate and activate MAP2Ks (MKK4 and MKK7), which phosphorylate and activate MAPKs (JNK). JNK phosphorolates and activates its canonical target JUN, which can then act as a proapoptotic transcription factor by promoting the transcription of pro-death genes (e.g. Bim, Faslg, and Bbc3). Jun deficiency or loss of function was significantly protective to RGCs after chronic ocular hypertension and axonal injury. Similarly, endoplasmic reticulum stress has been implicated in neurodegenerative diseases, including glaucoma. Prolonged endoplasmic reticulum stress promotes translation of DNA-damage-inducible transcript 3 (DDIT3, also known as CHOP), which can then act as a pro-apoptotic transcription factor. Ddit3 deficiency was moderately protective to RGCs after axonal injury and ocular hypertension. Dual deletion of Jun and Ddit3 conferred additive, near complete, and long-term protection to RGCs following optic nerve crush. Given the potential importance of EDN signaling in glaucomatous neurodegeneration, it is plausible that EDN causes RGC death via JUN and/or DDIT3 activation. Notably, both JUN and DDIT3 have been known to act downstream of EDN receptors. MAPKs (including JNK) and JUN were shown to be upregulated or activated in a variety of cell types, including cultured RGCs, after exposure to EDN. Therefore, JUN may play a role in regulating RGC death after EDN insult. The EDN system has also been shown to activate the endoplasmic reticulum stress response. Therefore, it is possible that JUN and/or DDIT3 are RGC intrinsic regulators of EDN-induced RGC death, similar to after glaucoma-relevant injuries. Here, we characterized the time course and extent of EDN insult and critically test the importance of JUN and DDIT3 in RGC death following EDN insult in vivo.

In addition to the apoptotic RGC-autonomous mechanisms triggered by EDN signaling, the cell types that respond to EDN ligands to ultimately cause RGC death remain unknown. EDN ligands cause vasoconstriction by binding to EDNRA expressed by vascular smooth muscle cells. Thinner retinal vessels and evidence of hypoxia have been demonstrated in animal models of chronic glaucoma. Importantly, JUN was found to be an important regulator of ischemia-induced neuronal death. Thus, it is possible that EDN elicits a hypoxic insult to the retina via EDNRA to ultimately cause JUN-dependent RGC loss. To clarify how EDN ligands may be acting to cause RGC loss, we characterized changes in retinal vessel diameter and hypoxia after EDN insult.

Materials and methods

Mice

Wild-type (WT) C57BL/6J mice and mice carrying a germline deletion of Ddit3 (The Jackson Laboratory, Stock# 005530) or floxed alleles of Jun (Junfl) were utilized for all experiments. All mice used were 2–6 months of age. Floxed alleles were recombined in the optic cup using Six3-cre (The Jackson Laboratory, Stock# 019755). All alleles were backcrossed >10 times to the C57BL/6J genetic background (>99% C57BL/6J), and all colonies were maintained by intercrossing. Mice were fed chow and water ad libitum and housed on a 12-h light-to-dark cycle. Roughly equal numbers of males and females were used for each experimental group. Animals were randomly assigned to experimental groups. Before experiments were performed, it was established that animals with pre-existing abnormal eye phenotypes (e.g. displaced pupil, cataracts) would be excluded from the study. All experiments were conducted in adherence with the Association for Research in Vision and Ophthalmology’s statement on the use of animals in ophthalmic and vision research and were approved by the University of Rochester’s University Committee on Animal Resources.

Intravitreal injections

Mice were anaesthetized with an intraperitoneal injection of 0.05 ml/10 g solution containing ketamine (20 mg/mL) and xylazine (2 mg/mL). Eyes were sterilized with 50% betadine solution made in 1X phosphate buffered saline (PBS), and were thoroughly flushed with 1X PBS. The conjunctiva at the temporal quadrant was cleared away with the bevel of a 30-gauge needle, and a small incision was made with the 30-gauge needle through the sclera and behind the limbus. Vitreous was allowed to drain, and any blood was wicked away. Five μL Hamilton syringes (Hamilton Company, 7633–01) with a blunt 33-gauge needle were used to perform intravitreal injections. The needle of the Hamilton syringe was inserted 1 mm into the incision site at a 45° angle toward the optic nerve, and was held in place for 30 s prior to injection. Care was taken to avoid contacting the lens with the Hamilton needle. Before experiments were performed, it was...
established that eyes with observable lens damage as a result of intravitreal injection would be excluded from the study. Over the course of 2 min (to prevent a sudden increase in intraocular pressure), 2 μL of 500 μM EDN1 (Sigma, E7764), diluted in sterile 1X PBS was injected into the vitreous. The Hamilton needle was held in place for 30 s following the injection, and the needle was removed from the eye over the course of 30 s. Antibiotic ointment was placed over the eye. The contralateral eye was injected with 2 μL of vehicle (sterile 1X PBS) with identical methods to serve as a control. Note: the investigator was masked to genotype while performing intravitreal injections.

**Fluorescein angiography**

Fluorescein angiography was performed as previously described. Mice were anaesthetized with an intraperitoneal injection of 0.05 mL/10 g solution containing ketamine (20 mg/mL) and xylazine (2 mg/mL). Mice were given an intraperitoneal injection of 0.2 μL/g fluorescein (25% Fluorescein Sodium) immediately prior to angiography. Retinal vasculature was photographed using a Micron III mouse retinal imaging system (Phoenix Research Labs).

**Hypoxia detection**

Hypoxia was assessed using pimonidazole HCl (Hypoxyprobe) according to manufacturer’s instructions. Ninety minutes prior to euthanasia, mice were given an intraperitoneal injection of (60 mg/kg) pimonidazole HCl diluted in sterile 1X PBS. Mice were then transcardially perfused with 20 mL saline solution and 20 mL 4% paraformaldehyde. Eyes were harvested and incubated in 4% paraformaldehyde for 30 min. Eyes were stored in 1X PBS until dissection. Hypoxia was detected using an antibody against pimonidazole (Table 1).

**Immunostaining and quantification**

Eyes were harvested and fixed in 4% paraformaldehyde in 1X PBS for 90 min. For retinal sections, the anterior segment was removed and the retina was kept in the optic cup for processing. Retinas were incubated in 10% sucrose (in 1X PBS) overnight, 20% sucrose overnight, and 30% sucrose for 3 days. Eyes were embedded in tissue freezing medium (General Data, TFM-5), frozen at −80°C, and cross-sectioned at 14 μm. Sections were collected on glass microscope slides, which were stored at −20°C. For hypoxia detection, one section every 84 μm was collected for immunofluorescence to ensure representation from the entire retina. Sections were blocked in 10% horse serum, 0.1% TritonX in 1X PBS for 3 h at room temperature and then incubated in primary antibody made in 10% horse serum, 0.1% TritonX overnight at 4°C. Sections were washed in 1X PBS and incubated in secondary antibody made in 1X PBS for 2 h at room temperature. Sections were then washed, counterstained with 4′,6-diamidino-2-phenylindole (DAPI), and mounted in Fluorogel in TRIS buffer (Electron Microscopy Sciences). A masked observer captured images. For hypoxyprobe immunofluorescence, images were exposure-matched.

Methodology for cell quantification in retinal sections was adapted from Harder et al. All sections analyzed were a maximum of 168 μm from the optic nerve head. Five equidistant 20× fields (444 μm) were captured per section; two at each periphery, two at each middle area, and one at the center. Four sections were analyzed per retina. The cell counter tool in ImageJ was used for cell quantification. For each section, cell counts were summed. The score of each retina was the average of the 4 sections’ summed cell counts normalized to the distance measured.

For whole mount staining, retinas were dissected free from the optic cup and blocked in 10% horse serum, 0.4% TritonX in 1X PBS overnight at 4°C. Retinas were incubated at 4°C for 72 h in primary antibody diluted in 10% horse serum, 0.4% TritonX in 1X PBS. Retinas were then washed and incubated overnight at 4°C in secondary antibody diluted in 1X PBS. Retinas were washed and

| Table 1: Summary of antibodies. |
|---------------------------------
| **Primary antibody (catalog number)** | **Concentration** | **Company** |
| Rabbit anti-cCASP3 (AF835) | 1:1000 | R&D Systems |
| Goat anti-CD31 (AF3628) | 1:1000 | R&D Systems |
| Goat anti-ChAT (AB144P) | 1:200 | Millipore |
| Mouse anti-JUN (BD610327) | 1:250 | Fisher Scientific |
| Rabbit anti-pimonidazole (PAb2627AP) | 1:200 | Hypoxyprobe |
| Rabbit anti-pJUN (92615) | 1:250 | Cell Signaling |
| Rabbit anti-RBPM (GTX118619) | 1:250 | GeneTex |
| Guinea pig anti-RBPM (1832-RBPM) | 1:250 | PhosphoSolutions |
| Goat anti-SOX2 (sc-17320) | 1:200 | Santa Cruz |
| **Secondary antibody (catalog number)** | | |
| Donkey anti-rabbit (A31572, A-21206) | 1:1000 | ThermoFisher |
| Donkey anti-guinea pig (706–605–148) | 1:1000 | Jackson |
| Donkey anti-goat (A21447) | 1:1000 | ThermoFisher |
| Donkey anti-mouse (A31570) | 1:1000 | ThermoFisher |
mounted ganglion cell layer-up in Fluorgel in TRIS buffer (Electron Microscopy Sciences). Note: for triple immunofluorescence, primary antibodies from three different host species were utilized, and secondary antibodies conjugated with fluorophores with 3 different excitation/emission frequencies were utilized.

As previously described, RBPMS+, SOX2+, and pJUN+ cells were quantified using eight 40× fields per retina, and cCASP3+RBPM+ cells were quantified using eight 20× fields per retina. Images were equally spaced 220 μm from the peripheral edge of the retina. The cell-counter tool in ImageJ was used for quantification. A masked observer captured and quantified images.

To assess changes in artery and vein diameter after EDN1 insult ex vivo, mice were trancardially perfused with 20 mL PBS and 20 mL 4% PFA 5 min after EDN1 injection. Retinas were processed for whole mount immunostaining as described above. Retinal artery and vein diameters were measured using the line segment measurement tool in ImageJ. Six measurements per CD31+ artery and vein were taken 240 μm, 305 μm, 370 μm, 435 μm, 500 μm, and 565 μm from the optic disc. Distance from the optic disc was chosen in order to include measurements before the approximate location of the first arterial bifurcations. Arteries and veins were identified by their distinct branching morphologies.

**Controlled optic nerve crush**

Controlled optic nerve crush (CONC) was performed as previously described. Mice were anesthetized with an intraperitoneal injection of 0.05 mL/10 g solution containing ketamine (20 mg/mL) and xylazine (2 mg/mL). Meloxicam (2 mg/kg) was administered subcutaneously prior to surgery. The optic nerve was exposed and crushed immediately behind the eye with self-closing forceps for 5 s. Antibiotic ointment was applied to the eyes after the procedure.

**Statistical analysis**

Data were analyzed using GraphPad Prism8 software. Power calculations were performed before experiments were conducted to determine appropriate sample size. Data from experiments designed to test differences between two groups (e.g. %RGC survival, %pJUN+RBPM+ cells, vessel diameters, ChAT+ cells/mm, SOX2+ cells/mm², and SOX2+ Müller glia/mm after PBS and EDN1 in WT mice; Figs. 1b, 2c, 4d, and 5) were subjected to an F test to compare variance and a Shapiro–Willk test to test normality to ensure appropriate statistical tests were utilized. %RGC survival (Fig. 1b), venous diameter (Fig. 4d), ChAT+ cells/mm (Fig. 5b–d), SOX2+ cells/mm² (Fig. 5e), and SOX2+ Müller glia/mm (Fig. 5f) were analyzed using unpaired two-tailed t tests. %pJUN+ RGCs (Fig. 2c) and
arterial diameter (Fig. 4d) were analyzed using Welch’s t test. Data from experiments designed to test differences among more than two groups across one condition (e.g. caspase 3 activation among WT, Ddit3−/−, and Jun−/− retinas after EDN1, Fig. 3a) were subjected to a Brown-Forsythe test to compare variance and a Shapiro–Wilk test to test normality to ensure an appropriate statistical test was utilized. Data were analyzed using a Kruskal–Wallis test with Dunn’s post hoc test. Data from experiments designed to detect differences among multiple groups and across multiple conditions (e.g. caspase 3 activation after PBS and EDN1 at multiple timepoints, RBPMS+ and RBPMS− pJUN+ cells after PBS and EDN1, pJUN+ and pJUN− cCASP3+ RBPMS+ cells after PBS and EDN1, % pJUN+ and %pJUN− cCASP3+ RBPMS+ cells after EDN1 and CONC, and %RGC survival across multiple genotype groups after PBS and EDN1; Figs. 1a, 2b, e, f, and 3b) were analyzed using a two-way ANOVA followed by Holm-Sidak’s post hoc tests. For these statistical tests, every possible comparison was made when relevant, and multiplicity adjusted P values are reported. In all cases, data met the assumptions of the statistical test used. P values < 0.05 were considered statistically significant. Throughout the manuscript, results are reported as mean ± standard error of the mean (SEM).

Results

EDN1 caused caspase 3 activation in RGCs and RGC loss

Experiments using in vivo approaches have demonstrated that EDN exposure causes RGC death4,6,21. However, the mechanisms responsible for eliciting apoptosis upon EDN insult remain unknown. To understand the mechanisms of glaucoma-relevant EDN-induced RGC death, the time course and extent of EDN injury were characterized in vivo. To accomplish this, wild-type (WT) C57BL/6J mice were intravitreally injected with 2 μL of 500 μM EDN1 diluted in 1X PBS (1 nmol EDN1). 1X PBS was intravitreally injected into the contralateral eye to serve as an internal vehicle control. Note, this injection paradigm was used for all experiments. In models of chronic ocular hypertension, RGCs die via apoptosis58, a process mediated by cleavage of caspase 3. Therefore, retinas were
immonoassayed for activated caspase 3 (cleaved caspase 3; cCASP3) at 3, 5, 10, and 14 days post-EDN1 and PBS injection. Retinas were counterstained for RBPMS, an RGC-specific marker, to ensure caspase 3 activation was specific to RGCs. Intravitreal EDN1 caused caspase 3 activation in RBPM5+ RGCs; this activation peaked 5 days post injection and was sparse by 14 days post injection. cCASP3+ RGCs were rarely present at any timepoint post-PBS injection (Fig. 1a). Based on the time course of caspase 3 activation in RGCs, the extent of RGC death was assessed 28 days post-EDN1. At this timepoint, there was a 26% decrease in RBPM5+ RGCs compared to PBS controls (Fig. 1b). Thus, intravitreal EDN1 was sufficient to cause a significant loss of RGCs by 28 days after insult.

EDN1 caused JUN activation in RGCs
The apoptotic mechanisms responsible for eliciting RGC death remain incompletely defined. JUN was shown to be important in RGC death after glaucoma-relevant insult, and EDN exposure caused JUN upregulation in cultured primary RGCs. To determine whether JUN plays a role in RGC death after EDN insult in vivo, retinas were immunoassayed for accumulated and activated (phosphorylated) JUN and RBPM5 1 day following PBS or EDN1 injection (prior to the onset of caspase 3 activation in RGCs, Fig. 1a). JUN accumulated and was activated (phosphorylated, pJUN) in 30% of RGCs 1 day following EDN1 injection (Fig. 2a–c), similar to the percentage of RGC death 28 days post-EDN injury (Fig. 1b). Of all pJUN+ cells, the vast majority (91.4%) were RBPM5+ RGCs, and a small population labeled an unknown cell type (Fig. 2b). JUN remained accumulated in RGCs 5 days post-EDN1 insult (Fig. 2d–f). To determine whether JUN+ RGCs were eventually the population of RGCs that apoptosed, retinas were immunoassayed for both JUN and cCASP3 5 days post-EDN1 insult. Of all cCASP3+ RGCs, 69% were also JUN positive (Fig. 2e). As a control, cCASP3+ RBPM5+ JUN+ cells were quantified after controlled optic nerve crush (CONC); an injury shown to cause RGC death via...
JUN signaling\(^{26}\). Similarly, only a portion (44%) of cCASP3+ RBPM5+ cells were also JUN+ (Fig. 2f). Given JUN accumulates in 100% of RGCs 1 day after CONC\(^{-}\), and only a portion of cCASP3+ RGCs are also JUN+ 5 days after CONC, it is likely that at this timepoint, cCASP3+ cells are in the process of degenerating, and proteins such as JUN are downregulated. Thus, JUN could feasibly contribute to EDN1-induced RGC death.

**EDN1-induced RGC death was largely JUN-dependent**

The cell death pathways governing RGC death after EDN insult are not well defined. Considering EDN insult caused activation of JUN in 30% of RGCs (Fig. 2a–c) and 69% of cCASP3+ RGCs were also JUN+ after EDN1 insult (Fig. 2d–f), it remained possible that JUN regulates EDN1-induced RGC death, similar to glaucoma-relevant RGC death. To determine whether EDN1-induced RGC death occurs via a JUN-dependent mechanism, Six3-cre\(^{-}\)Jun\(^{+/}\) (herein referred to as Jun\(^{-}\)/) and WT (Six3-cre\(^{+}\)Jun\(^{+/}\); Six3-cre Jun\(^{+/}\)) controls were intravitreally injected with EDN1 or PBS, and retinas were assessed for apoptotic RGCs and subsequent RGC loss. Jun deletion significantly lessened caspase 3 activation in RGCs 5 days post insult (Fig. 3a). Furthermore, retinal Jun deletion significantly attenuated RGC loss by 58% 28 days post insult (Fig. 3b).

Notably, Jun deletion did not protect all RGCs from EDN1-induced RGC death. This could be due in part to incomplete recombination of Jun\(^{-}\) alleles by Six3-cre. Six3-cre recombinant Jun\(^{-}\) alleles in 80% of RGCs\(^{26}\). Given Jun deletion by Six3-cre protected fewer than 80% of RGCs after EDN1 insult, it is likely that another apoptotic mechanism(s) is important in mediating EDN1-induced RGC death. Ddit3 (also known as CHOP), a pro-apoptotic transcription factor activated after prolonged endoplasmic reticulum stress, moderately contributed to RGC death after glaucoma-relevant insults\(^{26,29,30,60}\). Importantly, previous studies have demonstrated that JUN and Ddit3 additively contributed to RGC death after axonal injury (Ddit3 and Jun dual deletion prevented 75% of RGC death after RGC axonal insult\(^{26}\). Therefore, we tested the effect of Ddit3 deletion alone and in combination with Jun deletion on RGC survival after EDN insult. To accomplish this, mice with a homozygous germline deletion of Ddit3 (Ddit3\(^{-/-}\)) and WT littermate controls were utilized. Ddit3 deletion did not significantly reduce caspase 3 activation 5 days post-EDN1 compared to WT controls, and Ddit3 deletion did not significantly prevent RGC death 28 days post-EDN insult. To determine whether Ddit3 and Jun act in tandem to drive RGC death after EDN insult, Ddit3\(^{-/-}\) Jun\(^{-/-}\) eyes were intravitreally injected with EDN1 or PBS. Dual deletion of Ddit3 and Jun was significantly protective to RGCs 28 days post injection, but this was not significantly different than the effect of Jun deletion alone. Therefore, EDN1-induced RGC loss was largely JUN-dependent.

**EDN1 induced vasoconstriction and RGC hypoxia**

The mechanisms by which EDN1 induces JUN signaling and ultimately apoptosis remains unclear. The canonical role of the EDN system is to mediate vasoconstriction. EDN ligands are the most potent vasoactive peptides, and EDN has been shown to cause vasoconstriction through EDNRA expressed by vascular smooth muscle cells\(^{4,7,8,43,44}\). Importantly, JUN-JNK signaling has been shown to mediate neuronal death after ischemic insult\(^{47-51}\). Therefore, it is possible that EDN1 elicits a hypoxic insult to the retina, which can ultimately lead to RGC death via JNK-JUN signaling. To determine whether EDN1 elicited retinal vasoconstriction, fluorescein angiography was utilized at several timepoints post-intravitreal injection of either EDN1 or PBS. As previously reported in rats\(^{61-63}\) and rabbits\(^{64,65}\), intravitreal EDN1 caused rapid retinal vasoconstriction, which lasted at least 3 h post injection. Retinal vessels appeared normally reperfused after 6 h. No vascular changes occurred at any timepoint post-PBS (Fig. 4a). Retinal vessel constriction was confirmed ex vivo 5 min post injection. EDN1 caused significant reduction of arterial diameter (Fig. 4b–d). EDN1 did not change retinal venous diameter. This is not surprising, as EDN ligands cause vasoconstriction by binding to EDNRA expressed by vascular smooth muscle cells, which are abundant in arterial walls but not in veins and therefore elicit more potent vasoconstriction of arteries\(^{66,67}\). Because vasoconstriction restricts blood flow, pimonidazole HCl (Hypoxeprobe) was utilized to determine whether intravitreal EDN1 caused retinal hypoxia. Pimonidazole forms covalent adducts in cells with a partial pressure of oxygen <10 mmHg. EDN1-injured retinas had hypoxic RBPM5+ RGCs and Müller glia somas (labeled by SOX2) and processes beginning 3 h post injection (data not shown) and lasting at least out to 24 h (Fig. 4e, f), suggesting that EDN1-induced vasoconstriction caused a hypoxic insult in the retina.

**EDN1 did not cause loss of amacrine cells or Müller glia**

Chronic hypoxia has been shown to cause loss of retinal neurons; including RGCs and amacrine cells\(^{68-71}\). However, in glaucoma, neurodegeneration is specific to RGCs and does not affect other retinal neurons, such as amacrine cells\(^{72}\). Therefore, it was important to characterize whether EDN1 insult affects RGCs specifically, or whether EDN1 injures amacrine cells as well, potentially via a global retinal hypoxic insult. Therefore, choline acetyltransferase (ChAT) immunostaining was utilized to assess loss of amacrine cells and disruption of synaptic strata in the inner plexiform layer after EDN1 insult. After 28 days,
EDN1 did not cause loss of ChAT+ amacrine cells (in the inner nuclear layer or the ganglion cell layer) or appear to disrupt the synaptic layers of the inner plexiform layer (Fig. 5a–d). Because approximately 59% of neurons in the ganglion cell layer are displaced amacrine cells73, SOX2+ displaced amacrine cell counts were assessed in the ganglion cell layer following EDN insult. SOX2 labels starburst amacrine cells in the ganglion cell layer74, which is by far the most abundant displaced amacrine cell. Therefore, SOX2+ cells in the ganglion cell layer were used to examine the effect of EDN1 insult on amacrine cells. There was no significant difference in the number of SOX2+ displaced amacrine cells in the ganglion cell layer between EDN1 and PBS injected eyes 28 days after injection (Fig. 5e). Therefore, similar to glaucomatous neurodegeneration, EDN1 insult affected RGCs and did not appear to cause amacrine cell loss. In addition, because hypoxyprobe labeling was observed in SOX2+ Müller glia...
after EDN1 insult, it was important to determine whether EDN1 insult elicited loss of Müller glia in addition to RGCs. After 28 days, EDN1 did not cause significant loss of SOX2+ Müller glia (Fig. 5f). Therefore, EDN1 did not appear to cause a global retinal hypoxic insult.

**Discussion**

Endothelin has been implicated as a mediator of glaucomatous RGC death,\(^{1,2,4,6,13,14,34,75,76}\). Components of EDN signaling were upregulated in human,\(^{3,18-20}\) and animal models of glaucoma,\(^{1,2,6,14-17}\), and genetic deletion...
or antagonism of EDN receptors lessened glaucomatous damage in ocular hypertensive rodents. Several groups have demonstrated EDN’s capacity to kill RGCs and chronic ocular hypertension. Similarly, but to a lesser extent, the endoplasmic reticulum stress effector and transcription factor DDIT3 played a role in RGC death after axonal injury and ocular hypertension. Dual deletion of Jun and Ddit3 conferred near-complete protection to RGCs after axonal insult. MAPKs-including JNK- and Jun have been shown to act downstream of EDN receptors in multiple cell types, including RGCs. In addition, EDN receptors have been shown to potentiate the endoplasmic reticulum stress response, and Ddit3 has been shown to act downstream of EDN receptors. Therefore, it remained possible that Jun and/or Ddit3 mediate RGC death in response to EDN.

In the present study, Jun was activated in 30% of RGCs 1 day post-EDN1 (Fig. 2a–c), and Jun deletion significantly attenuated RGC caspase 3 activation and RGC loss (Fig. 3a, b). This protection (58% increased RGC survival) is approximately commensurate to levels of protection conferred by Jun deletion in models of axonal injury (48% protection 120 days post injury) and chronic ocular hypertension (47% protection). In contrast, we found Ddit3 deletion did not provide significant protection from EDN-induced RGC death. These data do not preclude the possibility that Ddit3 deletion protected a small portion of RGCs after EDN insult that was not detected with our experimental design. This possibility is not unlikely, as Ddit3 deletion protected only 25% of RGCs 120 days post-axonal insult and 20% of RGCs in ocular hypertensive mice. Nevertheless, these data suggest that Ddit3 did not govern the majority of RGC death following EDN insult. Future work should elucidate the upstream regulators of Jun activation and the downstream targets of Jun signaling to further clarify the molecular mechanisms governing RGC apoptosis in response to EDN signaling. For instance, MAP3K12 (DLK), MAP2Ks 4 and 7 (MKK4, MKK7), and MAPKs 9 and 10 (JNK2, JNK3) are upstream regulators of Jun activation and were shown to be important in mediating glaucoma-relevant RGC death, and are perhaps important in regulating EDN-induced RGC death.

Furthermore, it will be important to determine whether Jun deletion protects RGC axons as well as somas after EDN insult. Jun has been shown to regulate RGC somal degeneration, but not axonal degeneration, after RGC axonal injury and chronic ocular hypertension. Theoretically, if EDN1 injures RGCs at the level of the soma, Jun deletion would likely confer protection to RGC axons as well as somas. However, if EDN1 causes a primary injury to RGC axons, Jun deletion could potentially confer protection to RGC somas, but not axons. Further dissecting the role of Jun in the degeneration of RGC somas and axons will be important for understanding EDN1-induced RGC death, and can possibly classify the location of EDN1 insult to RGCs (somal or axonal).

In addition to the cell death pathways important in eliciting RGC death after EDN insult, the retinal cell types that respond to EDN ligand and ultimately cause RGC death remain unknown. A multitude of cell types express EDN receptors; retinal neurons (including RGCs) and macroglia are known to express EDNRB, while RGCs and retinal mural cells are known to express EDNRA. While it is possible that EDN ligands affect RGCs directly (via receptors expressed by RGCs), it is also possible that EDN ligands signal extrinsically to RGCs by affecting glia or vascular cells and eliciting neurotoxic downstream effects; ultimately causing JUN-mediated RGC death. Regardless of the primary cell type EDN1 acts upon to ultimately cause RGC death, the present study indicates that ultimately, JUN is important in RGC degeneration after EDN1 exposure.

The canonical role of EDN signaling is to mediate vasoconstriction. EDN ligands bind to EDNRA expressed by vascular mural cells, which elicits contraction of vascular smooth muscle cells and consequential vasoconstriction. Thinner retinal vessels and reduced blood flow have been reported in human and animal models of glaucoma. Notably, JNK-JUN signaling was found to contribute to neuronal death after ischemic insult to the rodent brain and retina. Therefore, it is possible that aberrant EDN signaling via mural cell-EDNRA contributes to reduced retinal blood flow in glaucoma, which could in turn perpetuate neurodegeneration via JNK-JUN signaling.

Consistent with previous reports using rats and rabbits, we found intravitreal EDN1 caused potent but transient arterial constriction in the mouse retina, which reperfused by 6 h post injection (Fig. 4a–d). Subsequently, EDN1 insult resulted in regions of hypoxic RGCs and Müller glia beginning 3 h (data not shown) and lasting at...
least 24 h post injection (Fig. 4b, c). Hypoxic glia and RGCs were also reported after induction of ocular hypertension, suggesting the potential importance of hypoxia in glaucoma pathology.\(^\text{5,46}\). RGC death did not necessarily occur in close proximity to major vessels after EDN insult, but it is possible that loss of blood flow or damage to minor vessels and capillary beds contributes to EDN pathology. Future studies should investigate the effect of EDN on retinal vessel integrity, and how any changes may play a role in EDN-induced RGC death. Severe hypoxia is known to cause RGC and amacrine cell loss; however, we observed RGC loss (Fig. 1b) but not loss of ChAT+ or SOX2+ amacrine cells after EDN1 insult (Fig. 5a–e); consistent with glaucomatous neurodegeneration. In addition, although Müller glia hypoxia was observed 24 h after EDN1 insult, Müller glia survival appeared unaffected 28 days after EDN1. Thus, in the present study, EDN1-induced cell death appeared to be specific to RGCs, similar to glaucoma pathology, and it remains possible that hypoxia plays a role in glaucomatous and EDN-induced RGC death. Future work should elucidate the role of EDNRA and hypoxia in mediating RGC death after EDN1 insult and in models of glaucoma.

Acknowledgements
We would like to acknowledge Alyssa Parker for her excellent technical support. This work was supported by EY027701 (R.T.L., G.R.H), Research to Prevent Blindness, an unrestricted grant to the Department of Ophthalmology, and National Institutes of Health Grants GM007356 (S.B.S-M.) and EY007125 (O.J.M.), and F31 EY030739 (O.J.M). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author details
1Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, USA. 2Cell Biology of Disease Graduate Program, University of Rochester Medical Center, Rochester, NY, USA. 3The Center for Visual Sciences, University of Rochester, Rochester, NY, USA. 4Medical Scientist Training Program, University of Rochester Medical Center, Rochester, NY, USA. 5The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, USA. 6Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 March 2020 Revised: 26 August 2020 Accepted: 27 August 2020 Published online: 26 September 2020

References
1. Howell, G. R. et al. Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma. Neurobiol. Dis. 71, 44–52 (2014).
2. Lau, J., Dang, M., Hockmann, K. & Ball, A. K. Effects of acute delivery of endothelin-1 on retinal ganglion cell loss in the rat. Exp. Eye Res. 82, 132–145 (2006).
3. Emre, M., Orgul, S., Haufschild, T., Shaw, S. G. & Flammer, J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br. J. Ophthalmol. 89, 60–63 (2005).
4. Sasaki, M. et al. Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits. Exp. Eye Res. 83, 629–637 (2006).
5. Howell, G. R. et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J. Clin. Invest. 121, 1249–1244 (2011).
6. Howell, G. R. et al. Radiation treatment inhibits monocye entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J. Clin. Invest. 122, 1246–1261 (2012).

Official journal of the Cell Death Differentiation Association
28. Akhter, R., Sanphui, P., Das, H., Saha, P. & Biswas, S. C. The regulation of p53 upregulated modulator of apoptosis by JNK-C-Jun pathway in beta-amyloid-induced neuron death. J. Neurochem. 134, 1091–1103 (2015).

29. Hu, Y. et al. Differential effects of unfolded protein response pathways on axon injury-induced death of retinal ganglion cells. Neuron 73, 445–452 (2012).

30. Marola, O. J., Syc-Mazurek, S. B. & Libby, R. T. DDT3 (CHOP) contributes to retinal ganglion cell somal loss but not axonal degeneration in DBA/2J mice. Cell Death Discov. 5, 140–140 (2019).

31. Gadde, A., Schinelli, S. & Gallo, V. Endothelin-1 regulates astrocyte proliferation and reactive gliosis via a JNK-C-Jun signaling pathway. J. Neurosci. 28, 2394–2408 (2008).

32. Cadwallader, K., Belman, J., McCormick, F. & Cook, S. Differential regulation of extracellular signal-regulated protein kinase 1 and Jun N-terminal kinase 1 by Ca2+- and protein kinase C in endothelin-stimulated Rat-1 cells. Biochem. J. 321, 795–804 (1997).

33. Wang, J., Ma, H. Y., Krishnamoorthy, R. R., Yorio, T. & He, S. A feed-forward regulation of endothelin receptors by c-Jun in human non-pigmented ciliary epithelial cells. J. Physiol. 527, 21521–21528 (2001).

34. He, S., Park, Y. H., Yorio, T. & Krishnamoorthy, R. R. Endothelin-mediated changes in gene expression in isolated purified rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 56, 6414–6416 (2015).

35. Sorokin, A., Kozlowski, P., Graves, L. & Philip, A. Protein-tyrosine kinase Pyk2 mediated endothelin-induced p38 MAPK activation in glomerular mesangial cells. J. Biol. Chem. 276, 21521–21528 (2001).

36. Kodama, H. et al. Selective involvement of p130Cas/Crk/Pyk2/c-Src in mediation through endothelin A receptor to JNK. Mol. Cell Biochem. 321, 51–59 (2008).

37. Jain, A., Olovsson, M., Burton, G. J. & Yung, H.-w. Endothelin-1 induces endothelin 1 signaling in retinal arteriolar smooth muscle. Invest. Ophthalmol. Vis. Sci. 53, 3059–3066 (2012).

38. Crist, A. M., Young, C. & Meadows, S. M. Characterization of arteminergic identity in the developing neonate mouse retina. Gene Expr. Patterns 23-24, 22–31 (2017).

39. Libby, R. T. et al. Susceptibility to neurodegeneration in a glaucoma is modulated by Bax gene dosage. PLoS Genet. 1, 17–26 (2005).

40. Kwong, J. M., Caprilli, J. & Piri, N. RNA binding protein with multiple splicing as a new marker for retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 51, 1052–1058 (2010).

41. Hu, Y. Axon injury induced endoplasmic reticulum stress and neurodegeneration. Neural Regen. Res. 11, 1557–1559 (2016).

42. Stewart, M. et al. Feedback via Ca2+-activated ion channels modulates endothelin 1 signaling in retinal arteriolar smooth muscle. Invest. Ophthalmol. Vis. Sci. 53, 309–366 (2012).

43. Bursell, S., Clemont, A. C., Oren, B. & King, G. L. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats. Invest. Ophthalmol. Vis. Sci. 36, 596–607 (1995).

44. Takagi, C. et al. Endothelin-1 action via endothelin receptor is a primary mechanism modulating retinal circulation response to hyperoxia. Invest. Ophthalmol. Vis. Sci. 37, 2099–2109 (1996).

45. Ciulla, T. A. et al. Endothelin-1-mediated retinal artery vasospasm and the rabbit retinoretinotensive. J. Ocul. Pharmacol. Ther. 1, 393–398 (2000).

46. Takei, K. et al. Analysis of vasococontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB receptor agonist. Life Sci. 53, PL111–PL115 (1993).

47. Yu, D.-Y. et al. Local modulation of retinal vein tone. Invest. Ophthalmol. Vis. Sci. 42, 412–419 (1991).

48. Yu, D.-Y. et al. Comparison of the vasoactive effects of the docosanoid unoinositol-1-phosphate and selective proteinase inhibitors on isolated perfused retinal arteries. Invest. Ophthalmol. Vis. Sci. 42, 1499–1504 (2001).

49. Spix, N. J. et al. Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygen-induced Retinopathy. Invest. Ophthalmol. Vis. Sci. 57, 3047–3057 (2016).

50. Ciulla, T. A. et al. Endothelin-1-mediated retinal artery vasospasm the rabbit retinoretinotensive. J. Ocul. Pharmacol. Ther. 1, 393–398 (2000).

51. Takei, K. et al. Analysis of vasococontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB receptor agonist. Life Sci. 53, PL111–PL115 (1993).

52. Yu, D.-Y. et al. Comparison of the vasoactive effects of the docosanoid unoinositol-1-phosphate and selective proteinase inhibitors on isolated perfused retinal arteries. Invest. Ophthalmol. Vis. Sci. 42, 1499–1504 (2001).

53. Spix, N. J. et al. Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygen-induced Retinopathy. Invest. Ophthalmol. Vis. Sci. 57, 3047–3057 (2016).

54. Rojo Arias, J. et al. VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. J. Neurochem. 130, 313–312 (1991).

55. Inoue, S. et al. Protective effects on the retina after ranibizumab treatment in an ischemia model. PLoS ONE 12, e0162407–e0162407 (2017).

56. Palmhof, M. et al. From Ganglion cell to photoreceptor layer: timeline of deterioration in a rat ischemia/reperfusion model. Front. Cell. Neurosci. https://doi.org/10.3389/fncel.2019.00174 (2019).

57. Jakobs, T. C., Libby, R. T., Ben, Y., John, S. W. & Masland, R. H. Retinal ganglion cell degeneration is not cell type specific in DBA/2J mice. J. Comp. Neurol. 171, 313–325 (2005).

58. Perez De Sevilla Muller, L., Shelley, J. & Weiler, R. Displaced amacrine cells of the mouse retina. J. Comp. Neurol. 505, 177–189 (2007).

59. Siegert, S. et al. Transcriptional code and disease map for adult retinal cell identity in the developing neonate mouse retina. Genesis 51, 567–571 (2017).

60. Siegert, S. et al. Transcriptional code and disease map for adult retinal cell identity in the developing neonate mouse retina. Genesis 51, 567–571 (2017).

61. Jassim, A. H. & Inman, D. M. Evidence of hypoxic glial cells in a model of ocular hypertension. Invest. Ophthalmol. Vis. Sci. 60, 1–15 (2019).

62. Chidlov, G., Wood, J. P. M. & Casson, R. J. Investigations into hypoxia and oxidative stress at the optic nerve head in a rat model of glaucoma. Front. Neurosci. 11, 478 (2017).

63. Bonello, B. M. p21CIP1/waf1 cell cycle inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9, 1180–1186 (2003).

64. Okuno, S., Saito, A., Hayashi, T. & Chan, P. H. The c-Jun N-terminal kinase signaling pathway mediates axon activation and subsequent neuronal apoptosis through interaction with bim after transient focal cerebral ischemia. J. Neurosci. 24, 8789 (2004).

65. Piotrowska, M. B. et al. Protective effects of a new C-Jun N-terminal kinase inhibitor in the model of global cerebral ischemia in rats. Molecules 24, 1722 (2019).

66. Guan, Q.-H. et al. The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res. 1035, 51–59 (2005).

67. Kim, B. J. et al. In vitro and in vivo neuroprotective effects of c-Jun N-terminal kinase inhibitors on retinal ganglion cells. Mol. Neurodegener. 11, 30 (2016).
78. Chen, Y. C., Chen, B. C., Huang, H. M., Lin, S. H. & Lin, C. H. Activation of PERK in ET-1- and thrombin-induced pulmonary fibroblast differentiation: inhibitory effects of curcumin. J Cell Physiol. https://doi.org/10.1002/jcp.28256 (2019).

79. Syc-Mazurek, S. B., Rausch, R. L., Fernandes, K. A., Wilson, M. P. & Libby, R. T. Mkk4 and Mkk7 are important for retinal development and axonal injury-induced retinal ganglion cell death. Cell Death Dis. 9, 1095 (2018).

80. Jonas, J. B. & Naumann, G. O. Parapapillary retinal vessel diameter in normal and glaucoma eyes. II. Correlations. Invest. Ophthalmol. Vis. Sci. 30, 1604–1611 (1989).

81. Surzenko, N., Crowl, T., Bachleda, A., Langer, L. & Pevny, L. SOX2 maintains the quiescent progenitor cell state of postnatal retinal Müller glia. Development 140, 1445 (2013).